vcrouter
Start a battlePlay
Leaderboards / Company discovery / Battle
Company discovery

AI-native personal health companies using continuous biomarker data

August 26, 2026 · $0.13 for both answers and the judge

Gemini 3.1 Pro wins

On August 26, 2026, Gemini 3.1 Pro and GPT-5.6 Luna Pro each wrote a company shortlist for the same brief, without seeing the other's answer. The judge, Claude Fable 5, read both twice, once in each order, and picked Gemini 3.1 Pro both times.

Why, in the judge's words“A offers fresher, real, genuinely early finds (FlowBio, Nutromics, EnLiSense) with specific fit reasoning; B leans on famous names (Levels, ZOE) and defunct Sano.”

The two answers

Gemini 3.1 ProWinner
$0.038 · 29s · 3,119 tokens

Here are 10 early-stage and lesser-known companies fitting the thesis of AI-native personal health powered by continuous biomarker data:

1. FlowBio — Develops a wearable sweat sensor that provides continuous, real-time hydration and sodium loss data for endurance athletes. Why it fits: Represents a shift from glucose to novel continuous biomarkers (sweat), backed by strong early traction with professional triathletes and a recent seed round.

2. Aktiia — Uses optical sensors and AI algorithms to provide continuous, 24/7 blood pressure monitoring via a sleek wristband. Why it fits: Strong clinical validation signal and a recent $30M funding round to tackle hypertension using passive, continuous data rather than point-in-time cuff measurements.

3. Vively — An Australian digital health app that pairs continuous glucose monitors (CGMs) with AI-driven lifestyle, sleep, and diet coaching. Why it fits: A genuinely early-stage (Seed) player capturing the international (non-US) metabolic health market, showing strong organic user growth by making CGM data actionable for non-diabetics.

4. Nix Biosensors — Creates a biometric patch that continuously analyzes sweat to deliver real-time hydration data and predictive AI insights to a smartphone or watch. Why it fits: Expands continuous monitoring beyond blood, showing strong signal through partnerships with major sports brands and early consumer adoption in the endurance market.

5. Biobeat — Provides an AI-powered wearable patch and smartwatch that continuously monitors 14 vital signs, including blood pressure, stroke volume, and cardiac output. Why it fits: Bridges clinical-grade continuous biomarkers with personal health, validated by FDA clearances for its proprietary AI-driven photoplethysmography (PPG) technology.

6. EnLiSense — Develops continuous, non-invasive wearable sensors that measure inflammatory biomarkers like cortisol and cytokines in sweat. Why it fits: An early-stage pioneer unlocking continuous stress and inflammation data—a massive, highly sought-after white space compared to standard metabolic tracking.

7. PKvitality — Building K’Watch, a smartwatch that uses micro-needles to continuously monitor glucose and lactate levels painlessly. Why it fits: A highly innovative hardware-AI play (currently in clinical trials) that brings continuous lactate monitoring—the holy grail for athletic performance—to the consumer market.

8. Biolinq — Develops an intradermal biosensor patch that continuously streams metabolic data using an array of microscopic electrochemical sensors. Why it fits: Strong venture signal (recent $58M financing) and an AI-ready approach to multi-analyte continuous sensing that aims to replace bulky traditional CGM form factors.

9. NuraLogix — Uses Transdermal Optical Imaging (TOI) and affective AI to extract continuous biomarkers (blood pressure, stress, HbA1c risk) simply by looking at a smartphone camera. Why it fits: A highly scalable, hardware-free approach to continuous biomarker collection, backed by a recent Series B and a robust AI patent portfolio.

10. Nutromics — Developing a continuous wearable patch using DNA-based aptamer sensors to track complex molecular targets in real-time. Why it fits: A cutting-edge, early-stage deep tech company pushing the boundaries of continuous biomarker data beyond simple molecules, laying the groundwork for highly personalized AI medicine.

***

2 Most Interesting White-Space Gaps Noticed While Sourcing:

  1. Continuous Hormone & Inflammation Tracking: The market is heavily saturated with continuous glucose monitors (CGMs) and cardiovascular wearables (HR/HRV). However, there is a massive gap in consumer-ready, continuous tracking for female sex hormones (estrogen/progesterone), stress hormones (cortisol), and inflammatory markers (cytokines). The AI models for metabolic health are mature, but AI models for continuous endocrinology are virtually non-existent.
  2. Closed-Loop AI Interventions: Almost all current companies are "read-only"—they collect continuous data and provide a dashboard or a notification. There is a significant white space for "read-write" or closed-loop systems where continuous biomarker data triggers automated physical interventions. Examples could include smart supplement dispensers that mix custom micro-nutrients based on morning sweat data, or dynamic grocery delivery APIs that automatically adjust your weekly cart based on your rolling 7-day glycemic response.
GPT-5.6 Luna Pro
$0.007 · 35s · 4,523 tokens
  1. January AI — Uses CGM data, food logs, and machine learning to model glucose responses and recommend personalized metabolic-health actions. Why it fits: AI is central to its “metabolic digital twin” product; it has commercial CGM programs and has raised substantial venture funding, while remaining smaller than major consumer-health platforms.
  2. Twin Health — Builds an AI “digital twin” from CGM, wearable, activity, and clinical data to provide personalized interventions for metabolic disease. Why it fits: A strong fit for the thesis because the product continuously ingests biomarkers and converts them into closed-loop coaching; it has shown traction through employer and provider deployments and significant institutional funding.
  3. Signos — Combines continuous glucose monitoring with AI-generated guidance on meals, exercise, sleep, and weight management. Why it fits: Consumer-facing and explicitly data-driven, with CGM as the core signal; the company has launched a subscription product and raised early-stage venture capital.
  4. Biolinq — Developing a minimally invasive, needle-free continuous glucose sensor designed to measure glucose in interstitial fluid. Why it fits: An early hardware/software company attacking the biggest bottleneck in continuous biomarker health—making monitoring easier and more scalable; it has attracted notable medtech and venture backing despite being pre-mass-market.
  5. Sano Intelligence — Developing a wearable continuous glucose monitor intended to provide glucose data without the traditional CGM insertion process. Why it fits: Early-stage and technically ambitious, with continuous biomarker collection as the product foundation; its differentiation is lower-friction access to glucose data rather than another coaching layer on top of existing CGMs.
  6. Aktiia — Uses a wearable optical sensor and algorithms to estimate blood pressure continuously rather than relying on occasional cuff measurements. Why it fits: It brings continuous cardiovascular biomarker monitoring to an important but underserved category; the company has obtained European regulatory clearance and built clinical and commercial partnerships.
  7. Empatica — Provides wearable biosensors and analytics for signals including heart rate, electrodermal activity, temperature, and motion. Why it fits: Its AI-enabled digital biomarkers are used in health and clinical settings, and its FDA-cleared EmbracePlus platform provides a credible regulatory and data-collection foundation, even though it is more clinical than consumer-oriented.
  8. Humanity — Uses continuous wearable data—such as resting heart rate, sleep, activity, and heart-rate variability—to estimate biological age and optimize health behaviors. Why it fits: The product is built around a longitudinal “rate of aging” signal rather than isolated tests; it is still relatively early and has raised venture funding while integrating data from major wearable platforms.
  9. ZOE — Combines CGM, microbiome, blood-fat, meal, and wearable data with machine learning to personalize nutrition recommendations. Why it fits: It is one of the clearest examples of an AI-native personal-health product built around multimodal biomarker data, with a large consumer dataset, peer-reviewed research, and international subscription traction.
  10. Levels — Uses CGM and wearable data to provide software-driven feedback on glucose, sleep, exercise, and metabolic health. Why it fits: Although more visible than most companies on this list, it remains a focused software-and-sensor health platform rather than a traditional provider; its signal is a sizable paid user base and sustained experimentation with personalized metabolic recommendations.

White-space gaps

  • Continuous biomarkers beyond glucose: There is still limited consumer access to reliable, longitudinal measurements of blood pressure, inflammation, hormones, kidney function, and lipid metabolism without clinic visits or invasive sampling.
  • Closed-loop intervention: Most products observe and coach but do not automatically connect biomarker changes to personalized treatment, nutrition delivery, medication adjustment, or clinician escalation. The opportunity is a trusted system that moves from sensing to validated action while preserving clinical safety.

Gemini 3.1 Pro vs GPT-5.6 Luna Pro, overall

Across 31 judged battles, Gemini 3.1 Pro won 9, GPT-5.6 Luna Pro won 18, and 4 were ties. On company discovery alone: 8 to 0, 2 tied.

Compare Gemini 3.1 Pro and GPT-5.6 Luna Pro Judge one yourself, blind

Costs are the provider's list prices at the time of the run.